Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 46: 1588-1596, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (20)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Meijer, W. G.
Right arrow Articles by de Vries, E. G.E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Meijer, W. G.
Right arrow Articles by de Vries, E. G.E.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
(Clinical Chemistry. 2000;46:1588-1596.)
© 2000 American Association for Clinical Chemistry, Inc.


Articles

Discriminating Capacity of Indole Markers in the Diagnosis of Carcinoid Tumors

Wim G. Meijer1, Ido P. Kema2,a, Marcel Volmer2, Pax H.B. Willemse1 and Elisabeth G.E. de Vries1

Departments of
1 Medical Oncology and
2 Pathology and Laboratory Medicine, University Hospital Groningen, 9700 RB Groningen, The Netherlands.
a Address correspondence to this author at: Department of Pathology and Laboratory Medicine, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands. Fax 31-50-3612290; e-mail i.p.kema{at}lab.azg.nl

Background: We evaluated the discriminating capacity of the indole markers urinary 5-hydroxyindoleacetic acid (5-HIAA), urinary serotonin, and platelet serotonin in the diagnosis of carcinoid tumors.

Methods: Indole markers were measured in 688 patients with suspected carcinoid disease. The initial values of indole markers from patients in whom a carcinoid tumor was confirmed during follow-up (n = 98) were used for ROC analysis. Two groups served as reference populations. The first consisted of 45 healthy individuals ("healthy controls"). The second was a random sample of 40 patients, drawn from the 590 (688 minus 98) patients with carcinoid-like symptoms but without a carcinoid tumor ("clinically suspected patients").

Results: ROC curve analysis showed platelet serotonin to have the highest discriminating capacity, especially in foregut carcinoids. Cutoff values for platelet serotonin obtained from ROC analysis with healthy controls as reference group (5.4 nmol/109 platelets) gave a sensitivity of 74%, specificity of 91%, positive predictive value of 63%, and negative predictive value of 95% when applied to the initial 688 patients. Using the cutoff value with the clinically suspected patients as the reference group (9.3 nmol/109 platelets) gave a sensitivity of 63%, specificity of 99%, positive predictive value of 89%, and negative predictive value of 93%. Indole markers were increased in 169 (25%) of 688 patients. In 76 (45%) of these 169 patients, a carcinoid tumor was present. Slight increases of markers were associated with non-carcinoid neuroendocrine tumors, non-neuroendocrine tumors, and disturbed bowel motility.

Conclusions: ROC curve analysis shows that platelet serotonin is the most discriminating indole marker for the diagnosis of carcinoid tumors. Platelet serotonin especially improves the diagnosis of carcinoids producing small amounts of serotonin.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Pharmacol. Exp. Ther.Home page
D. Zolkowska, M. H. Baumann, and R. B. Rothman
Chronic Fenfluramine Administration Increases Plasma Serotonin (5-Hydroxytryptamine) to Nontoxic Levels
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 791 - 797.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
J. M. Zuetenhorst and B. G. Taal
Metastatic Carcinoid Tumors: A Clinical Review
Oncologist, February 1, 2005; 10(2): 123 - 131.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
I. P. Kema, W. G. Meijer, G. Meiborg, B. Ooms, P. H.B. Willemse, and E. G.E. de Vries
Profiling of Tryptophan-related Plasma Indoles in Patients with Carcinoid Tumors by Automated, On-Line, Solid-Phase Extraction and HPLC with Fluorescence Detection
Clin. Chem., October 1, 2001; 47(10): 1811 - 1820.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.